Authored by Karl Simpson
Epigenetics is an area which is receiving a good deal of interest currently, not only in the area cancer research but also in other therapeutic areas too, such as autoimmune and inflammation. Massachusetts based Syndax Pharmaceuticals develops epigenetic therapies for treatment-resistant cancers. The company’s lead product is Entinostat, for which it holds the worldwide rights, is an oral, highly selective histone deacetylase (HDAC) inhibitor in late-stage clinical development for the treatment of advanced breast cancer and lung cancer. Entinostat has been studied in more than 800 cancer patients where objective tumor responses have been observed in both solid and haematologic malignancies.
This progress has netted the Syndax a series B financing round of $26.6m, with investment coming from Domain Associates, MPM Capital, Forward Ventures, and RMI. The company intends to advance its late-stage pipeline, which will include the beginning of an NDA-enabling Phase III study of entinostat in metastatic breast cancer. In the completed Phase II ENCORE 301 study, entinostat was shown to extend both PFS and OS when added to exemestane in postmenopausal women with estrogen receptor-positive (ER+) metastatic breast cancer whose cancer had cancer had progressed after treatment with a non-steroidal aromatase inhibitor.
Arlene Morris, Syndax’s CEO said “The series B financing enables us to continue to advance entinostat toward registration, where we believe the opportunity in breast cancer and lung cancer alone exceeds $2bn”.